Filing Flows › Biocryst Pharmaceuticals (BCRX) › Q2 2026
Biocryst Pharmaceuticals (BCRX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Biocryst Pharmaceuticals (BCRX) reported revenue of $218M for the second quarter 2026 (Q2 2026), +34% from a year earlier and +40% from the quarter before. Operating margin was 45.1%, net earnings $78.4M (35.9% of revenue).
Biocryst Pharmaceuticals, Q2 2026: revenue $218M (+34% year over year), operating margin 45.1%, net earnings $78.4M, operating cash flow $104M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $218M | +40% | +34% |
| Operating profit | $98.5M | — | +231% |
| Net earnings | $78.4M | — | 15× |
| Operating cash flow | $104M | — | +153% |
| Free cash flow | $104M | — | +153% |
What changed
Revenue was $218.2M in Q2 2026, up 34% year over year and up 40% from the previous quarter. ORLADEYO was the largest line at 72% of revenue. License and other revenues added $59.8M year over year (up 6480%), 109% of the total change.
Operating profit was $98.5M, a 45.1% margin (up 26.9 points year over year). Of the extra revenue versus Q2 2025, 125% reached operating profit, above the 18% margin then. Total costs fell 10% while revenue rose 34%. The fastest-growing cost line was Cost of revenue (+37%). Net earnings were $78.4M, up 1442% year over year. The effective tax rate was 1.4%.
Operating cash flow was $104.3M (up 153% year over year), 133% of net earnings. Non-cash charges added back $513K of depreciation and amortization and $14.7M of share-based compensation. Working capital and other items added $10.7M. Capital expenditures of $209K left free cash flow of $104.1M.
Questions
What was Biocryst Pharmaceuticals' revenue in the second quarter 2026?
Biocryst Pharmaceuticals (BCRX) reported revenue of $218M for the second quarter 2026 (Q2 2026), +34% from a year earlier and +40% from the quarter before.
Was Biocryst Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $98.5M (45.1% of revenue) and net earnings $78.4M.